VU 0155041CAS# 1093757-42-6 |
- FLAG tag Peptide
Catalog No.:BCC2562
CAS No.:98849-88-8
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1093757-42-6 | SDF | Download SDF |
| PubChem ID | 888023 | Appearance | Powder |
| Formula | C14H15Cl2NO3 | M.Wt | 316.18 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in 1eq. NaOH and to 100 mM in DMSO | ||
| Chemical Name | (1R,2S)-2-[(3,5-dichlorophenyl)carbamoyl]cyclohexane-1-carboxylic acid | ||
| SMILES | C1CCC(C(C1)C(=O)NC2=CC(=CC(=C2)Cl)Cl)C(=O)O | ||
| Standard InChIKey | VSMUYYFJVFSVCA-NWDGAFQWSA-N | ||
| Standard InChI | InChI=1S/C14H15Cl2NO3/c15-8-5-9(16)7-10(6-8)17-13(18)11-3-1-2-4-12(11)14(19)20/h5-7,11-12H,1-4H2,(H,17,18)(H,19,20)/t11-,12+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent, positive allosteric modulator/allosteric agonist at mGlu4 receptors (EC50 = 798 and 693 nM at human and rat mGlu4 receptors respectively). Active in in vivo models of Parkinson's disease following i.c.v. administration. Also available as sodium salt 3311. |
VU 0155041 Dilution Calculator
VU 0155041 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.1628 mL | 15.8138 mL | 31.6276 mL | 63.2551 mL | 79.0689 mL |
| 5 mM | 0.6326 mL | 3.1628 mL | 6.3255 mL | 12.651 mL | 15.8138 mL |
| 10 mM | 0.3163 mL | 1.5814 mL | 3.1628 mL | 6.3255 mL | 7.9069 mL |
| 50 mM | 0.0633 mL | 0.3163 mL | 0.6326 mL | 1.2651 mL | 1.5814 mL |
| 100 mM | 0.0316 mL | 0.1581 mL | 0.3163 mL | 0.6326 mL | 0.7907 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- SRT2104 (GSK2245840)
Catalog No.:BCC1950
CAS No.:1093403-33-8
- Vibralactone B
Catalog No.:BCN6748
CAS No.:1093230-95-5
- LKB1 (AAK1 dual inhibitor)
Catalog No.:BCC1705
CAS No.:1093222-27-5
- 3-Hydroxy-4,15-dinor-1(5)-xanthen-12,8-olide
Catalog No.:BCN1625
CAS No.:1093207-99-8
- HNGF6A
Catalog No.:BCC8021
CAS No.:1093111-54-6
- B-Raf inhibitor 1
Catalog No.:BCC4182
CAS No.:1093100-40-3
- PLpro inhibitor
Catalog No.:BCC5302
CAS No.:1093070-14-4
- Angelol M
Catalog No.:BCN8271
CAS No.:1092952-64-1
- 7,2',4'-Trihydroxy-5-methoxy-3-phenylcoumarin
Catalog No.:BCN1626
CAS No.:1092952-62-9
- Ruxolitinib phosphate
Catalog No.:BCC1912
CAS No.:1092939-17-7
- Ruxolitinib sulfate
Catalog No.:BCC1913
CAS No.:1092939-16-6
- PP121
Catalog No.:BCC4980
CAS No.:1092788-83-4
- gamma-secretase modulator 2
Catalog No.:BCC1584
CAS No.:1093978-89-2
- CYM 5442 hydrochloride
Catalog No.:BCC7722
CAS No.:1094042-01-9
- SCH-1473759
Catalog No.:BCC1934
CAS No.:1094069-99-4
- Fmoc-His(Trt)-OH
Catalog No.:BCC3501
CAS No.:109425-51-6
- Fmoc-Orn(Boc)-OH
Catalog No.:BCC3533
CAS No.:109425-55-0
- Fmoc-His(Trt)-OPfp
Catalog No.:BCC3502
CAS No.:109434-24-4
- BIX 02188
Catalog No.:BCC2550
CAS No.:1094614-84-2
- BIX 02189
Catalog No.:BCC2549
CAS No.:1094614-85-3
- 3'-Methyl-4-O-methylhelichrysetin
Catalog No.:BCN4062
CAS No.:109471-13-8
- JNJ-31020028
Catalog No.:BCC5516
CAS No.:1094873-14-9
- PF-04449913
Catalog No.:BCC5154
CAS No.:1095173-27-5
- Rac1 Inhibitor W56
Catalog No.:BCC5886
CAS No.:1095179-01-3
[Lessons learned from the evacuation of the VU University Medical Centre after flooding].[Pubmed:28224872]
Ned Tijdschr Geneeskd. 2017;161:D861.
On 8 September 2015, flooding of the lower floors of the VU University Medical Center in Amsterdam caused serious damage to many vital technical services, such as water and power supplies. The decision was made to completely evacuate the university hospital. This paper describes the chronology and events of that day and shares a number of important lessons that were learned, in order to help readers to optimise crisis organisation in their own institutions. A serious situation or disaster can never be standardised in protocols or manuals; flexibility, improvisation and confidence in one another's expertise and commitment are therefore essential.
Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4.[Pubmed:18664603]
Mol Pharmacol. 2008 Nov;74(5):1345-58.
Parkinson's disease (PD) is caused by the death of dopamine neurons in the basal ganglia and results in motor symptoms such as tremor and bradykinesia. Activation of metabotropic glutamate receptor 4 (mGluR4) has been shown to modulate neurotransmission in the basal ganglia and results in antiparkinsonian effects in rodent PD models. N-Phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC) is a positive allosteric modulator (PAM) of mGluR4 that has been used to further validate the role of mGluR4 in PD, but the compound suffers from a lack of selectivity, relatively low potency, and poor solubility. Via high-throughput screening, we discovered more than 400 novel PAMs of mGluR4. Compounds derived from a novel chemical scaffold were characterized in vitro at both rat and human mGluR4 using two distinct assays of mGluR4 function. The lead compound was approximately 8-fold more potent than PHCCC, enhanced the potency of glutamate at mGluR4 by 8-fold, and did not show any significant potentiator or antagonist activity at other mGluR subtypes. Resolution of the regioisomers of the lead revealed that the cis regioisomer, (+/-)-cis-2-(3,5-dichlorphenylcarbamoyl)cyclohexanecarboxylic acid (VU0155041), contained the majority of the mGluR4 PAM activity and also exhibited partial agonist activity at mGluR4 at a site that was distinct from the glutamate binding site, suggesting that this compound is a mixed allosteric agonist/PAM of mGluR4. VU0155041 was soluble in an aqueous vehicle, and intracerebroventricular administration of 31 to 316 nmol of VU0155041 dose-dependently decreased haloperidol-induced catalepsy and reserpine-induced akinesia in rats. These exciting results provide continued support for mGluR4 as a therapeutic target in PD.
